26th - 29th October,2021

5th Annual MarketsAndMarkets Virtual Next-Gen Immuno-Oncology Conference-UK

Our 5th Annual MarketsandMarkets Next Gen Immuno-Oncology Virtual Congress to be held on 26 - 29 October 2021 would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors.

users

With more than 20 speakers across the world from pharma, bio-pharma and biotech companies, the congress will discuss the latest updates in development of ADC’s, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors and Cellular Therapy  

users

Meet and network with experts from leading universities and industry sharing their knowledge on Preclinical and Translational Immuno-Oncology Developments, Next Gen CAR-T Cell Therapy, Immune Checkpoint Inhibitors, Monoclonal and Bispecific Antibodies and more.

users

A platform to meet experts from Pharma, bio-pharma and biotech companies and increase your learning in Monoclonal and Bispecific Antibodies, Cell Therapy and Immune Checkpoint Inhibitors.

This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions.

WHAT TO EXPECT
Key Highlights
  • Updates in development of ADC’s and Bispecific Ab’s
  • Immune Checkpoint Inhibitors and Combinations
  • Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immune checkpoint modulators)
  • Biomarkers and Personalized Medicine in IO
  • CAR-T Cell therapy, TCR Based-Cell Therapy
  • Tumor microenvironment and Oncolytic Viruses
Who Should Attend?

CSO, Director, VP, Head, Senior Investigator, Manager, Principal Scientist, Team Leader, Group Leaders, Professors, Assistant Professors, Research fellows, PhDs working on

  • Monoclonal and Bispecific Antibodies
  • Cell Therapy
  • Immune Checkpoint Inhibitors
Why Attend?
  • Exclusive conference to learn about antibodies, cellular therapy and immune-checkpoint research under one roof
  • Find out new case studies of immune-oncology projects in development
  • Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you
  • Explore the latest platforms and technologies on the market for development
  • Discuss the best tool for your research in immune-oncology
  • Share your work and achievements with your industry peers in the Poster Session
CONFERENCE SPEAKERS
Speakers
Lindy Durrant

Lindy Durrant

Professor, Cancer Immunotherapy
University of Nottingham, UK

Lindy Durrant

Professor, Cancer Immunotherapy
University of Nottingham, UK
Stefan Glueck

Stefan Glueck

Senior Vice President, Global Medical Affairs
Celgene

Stefan Glueck

Senior Vice President, Global Medical Affairs
Celgene
SPONSORS
Leading Partner
example-image

BIOCYTOGEN

example-image

Ultivue

example-image

Larvol

example-image

Proteome Sciences

example-image

GemPharmatech

Visiting Partners
example-image

Quanterix

Speaking Partner
example-image

NeoGenomics

example-image

PHC Group

example-image

TransCure bioServices

example-image

CELLINK

example-image

evorion biotechnologies GmbH

Primary Partner
example-image

Personalis

example-image

HalioDx

example-image

International Drug Development Institute

example-image

Predicine

Meeting Partner
example-image

Cytiva

PAST EVENT GALLERY